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After entering the artery wall, monocytes differentiate into macrophages in processes that are mediated by macrophage colony stimulating factor (CSF) and granulocyte-macrophage CSF. 2 Macrophages express a range of scavenger receptors that bind and internalize modified LDL in an unregulated manner. This leads to a progressive accumulation of lipids in the macrophages and the formation of foam cells: the hallmark cells of atherosclerotic lesions.
The results of numerous epidemiological studies have established that high density lipoprotein (HDL) levels correlate inversely with the risk of developing cardiovascular disease. 3 This relationship reflects several functions of HDL, the most extensively studied of which is their ability to remove excess cholesterol from cells, such as macrophages in the artery wall, in the first step of the reverse cholesterol transport pathway. 4 In addition to their lipid transporting properties, HDL have antioxidant and antithrombotic properties. 5, 6 They are also important for maintaining normal endothelium-dependent vasoreactivity, inhibiting endothelial cell apoptosis, and contributing to the repair of damaged endothelium. 6, 7 In recent years it has become increasingly apparent that HDL also have potent antiinflammatory properties. This has been demonstrated in vitro as well as in vivo. For example, the cytokine-induced expression of VCAM-1, ICAM-1, and E-selectin in cultured human umbilical vein endothelial cells (HUVECs) is inhibited by HDL in a concentration-dependent manner. 8 HDL also reduce the binding of monocytes to the surface of tumor-necrosis factor-␣-activated HUVECs, 9 and their lysosphingolipid cargo has recently been shown to inhibit aortic MCP-1 expression. 10 The article by Murphy et al in the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology now reveals that HDL can also prevent inflammatory responses by acting directly on monocytes. 11 In this study Murphy et al show that HDL isolated from normal subjects, lipid-free apoA-I (the main apolipoprotein of HDL), and reconstituted HDL (rHDL) containing apoA-I complexed with phosphatidylcholine all potently inhibit expression of the integrin CD11b (also known as Mac-1) on the monocyte surface. The specificity of this observation was confirmed by showing that neither phosphatidylcholine liposomes nor BSA can inhibit monocyte CD11b expression. The physiological relevance of the observation was strengthened by demonstrating that the HDL-mediated inhibition of CD11b expression prevented the monocytes from binding to cultured human coronary artery endothelial cells, although it is difficult to determine to what extent this reflects an HDL-mediated reduction in endothelial expression of ICAM-1, which is a key ligand for CD11b. 12 It is equally relevant that the present studies do not allow us to differentiate between the potential antiinflammatory effects of HDL on specific monocyte subpopulations and their ultimate impact on atherogenesis. 13 Murphy et al also established that the inhibition of CD11b expression by apoA-I, but not HDL, was most likely secondary to cholesterol efflux. This conclusion was reached by depleting the monocytes of cholesterol with ␤-cyclodextrin, or by blocking activity of the ATP binding cassette transporter ABCA1 with a neutralizing antibody that specifically prevents cholesterol efflux. The finding that HDL did not inhibit monocyte activation by a mechanism that involves cholesterol efflux suggests that other, as yet unidentified, receptors or transporters are also involved.
These results differ in some respects from what has been reported for the inhibition of inflammatory responses in endothelial cells by HDL. In the present study Murphy et al established that lipid-free apoA-I, but not phospholipid liposomes, inhibit monocyte activation in vitro. Earlier reports from our group have, by contrast, shown that rHDL and small unilamellar phosphatidylcholine vesicles, but not lipid-free apoA-I, inhibit inflammation in activated HUVECs in vitro. 14 Although the finding that infusion of lipid-free apoA-I inhibits endothelial inflammation to the same extent as rHDL in vivo appears to be at odds with our in vitro observation, this most likely reflects no more than the rapid lipidation of the injected apoA-I to form new HDL particles. 15 Considering that Murphy et al found that lipid-free apoA-I but not phospholipid liposomes inhibit monocyte CD11b expression, whereas our earlier observations demonstrated that phospholipid vesicles, but not lipid-free apoA-I, inhibit endothelial cell adhesion molecule expression, the possibility that HDL prevent monocyte and endothelial cell activation by different mechanisms needs to be considered. Although this has obvious implications for the design of antiinflammatory apoA-I mimetic peptides, there is preliminary evidence suggesting that it may not necessarily be a cause for concern as the apoA-I mimetic peptide L37pA has been shown to reduce CD11b expression in monocytes 11 as well as in cultured endothelial cells. 16 In conclusion, this study by Murphy et al adds to a growing body of evidence that HDL and apoA-I protect against cardiovascular disease by mechanisms that extend well beyond their involvement in cholesterol transport. It remains to be seen whether the ability of HDL to inhibit monocyte activation proves to be important for reducing the debilitating symptoms and economic cost associated with acute coronary syndromes and other inflammatory diseases.
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